TrialJournal of hematology & oncology2024

Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.

Feng Bi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.